07:25:51 EDT Thu 18 Aug 2022
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Global Health Clinics Ltd (2)
Symbol MJRX
Shares Issued 33,631,630
Close 2021-03-23 C$ 0.125
Recent Sedar Documents

Global Health appoints Jahns head of Wonder Scientific

2021-04-29 20:45 ET - News Release

Mr. Jatinder Dhaliwal reports

GLOBAL HEALTH ANNOUNCES MANAGEMENT CHANGES AT WONDER SCIENTIFIC, INCLUDING THE APPOINTMENT OF SENIOR PHRAMA EXEC DR. BRIAN JAHNS

Global Health Clinics Ltd. has made management changes at its Wonder Scientific division. Wonder Scientific was acquired by the company on Jan. 20, 2021 (see Jan. 20, 2021, news release), and is focused on sourcing and securing access to federally licensed work and bench space required for formulation and manufacturing work in the business-to-business sales channels of the active pharmaceutical ingredients (API) industry, including psilocybin. In order to align the strategic goals of the company and Wonder Scientific in the biopharmaceutical industry, the company has made significant management changes. Tegan Adams, a co-founder of Wonder Scientific, is no longer with the company or Wonder Scientific. Istok Nahtigal and Angela Caruk, former consults of Wonder Scientific, are also no longer consulting for Wonder Scientific.

The company continues in discussion with consultant Dr. Andrew Riseman, a Wonder Scientific consultant, with a view to continuing to advance the continuing relationship between the parties toward the development of research on optimizing production for psilocybin mushrooms, mycelium productions and the creation of a genetics library. To date, Dr. Riseman has curated a library of 18 genotypes of Psilocybe spore cultures on behalf of Wonder Scientific and has applied for a controlled substances licence from Health Canada under which his work with Wonder Scientific will proceed. Dr. Riseman's current consulting agreement with Wonder Scientific will expire at the end of May, 2021.

The company is pleased to announce that its Wonder Scientific division will now be led by Dr. Brian Jahns. Dr. Jahns brings more than 20 years of business leadership and biopharmaceutical expertise to his role in overseeing the overall business development of Wonder Scientific, including its key corporate objectives of sourcing and securing access to federally licensed work and bench space required for formulation and manufacturing work in the business-to-business sales channels of the industry. Importantly, Dr. Jahns will focus on the custom creation of naturally derived APIs to supply the growing global clinical and commercial demand for psychedelics.

"I believe strongly in the potential of psychedelic therapeutics, and I'm excited by the prospect of working with Jay and his team," said Dr. Jahns regarding his new role with Wonder Scientific.

Dr. Jahns has held senior leadership roles in the biopharmaceutical industry, including Zyus, Trillium Therapeutics and Roche Canada, and has been deeply involved in the successful launch and growth of several successful compounds, including anti-viral agents, transplant drugs and anti-cancer biologics, and developing targeted therapies for previously untreated diseases. Dr. Jahns has led preparations for commercialization, led efforts to procure commercial-scale manufacturing and led business partnering activities for several compounds. He is currently chief business officer at Entheon Biomedical, and is a licensed pharmacist, doctor of pharmacy and clinical toxicologist. Dr. Jahns also advises the University of Toronto MaRS discovery district, mentoring start-up biopharma and diagnostic companies, and has been published in numerous scientific journals.

"An executive of Dr. Jahns's acumen brings invaluable expertise to Wonder Scientific as we work towards our goal of developing naturally derived APIs," said chief executive officer Jay Dhaliwal.

The company continues to seek talented team members who are aligned with the company's vision of Wonder Scientific becoming as a supplier of clean-start Psilocybe genetics to the psychedelics research and novel drug development industry. If the company is unable to obtain this expertise, it could delay the development of the company's operations and could have a material adverse effect on the business of the company. The company will provide further updates on its advancements at Wonder Scientific as this business continues to move forward.

We seek Safe Harbor.

© 2022 Canjex Publishing Ltd. All rights reserved.